🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseSemaglutide liver fat quantification — MRI-PDFF data from multiple trials Page 5

Semaglutide liver fat quantification — MRI-PDFF data from multiple trials

MASHdoc_SA Sat, Mar 7, 2026 at 9:22 AM 22 replies 672 viewsPage 5 of 5
kevin_tulsa
Member
489
2,123
Jun 2024
Tulsa, OK
Mar 7, 2026 at 4:27 PM#21

cory_ATX — that is really helpful context on Semaglutide liver fat. Follow-up question: what labs did your doctor order to monitor this?

I am in a similar situation (just started) and trying to set realistic expectations.

Last edited: Mar 7, 2026 at 6:27 PM
23 9fiona_glasgow, Dr.RheumBOS, greg_boulder and 20 others
Reply Quote Save Share Report
TinaHashiRN
Member
345
1,567
Sep 2024
Raleigh, NC
Mar 7, 2026 at 4:44 PM#22

To answer HealthEcon_DC's question specifically:

From a clinical standpoint, Semaglutide liver fat is an area where we have good evidence.

The short answer: baseline labs + quarterly monitoring is the standard of care.

The longer answer involves understanding the mechanism of action at the receptor level, which I am happy to elaborate on if helpful.

Last edited: Mar 7, 2026 at 10:44 PM
9 6mike_mod, SarahChen_PharmD, sarah.morrison and 6 others
Reply Quote Save Share Report
Dr.PulmRoch
Member
456
2,345
Jun 2024
Rochester, MN
Mar 7, 2026 at 5:01 PM#23

Thank you kevin_tulsa! This is incredibly helpful. Bookmarking for later. 🙏

6 21AttorneyGrant, DebRD_ATL, KristenIndy and 3 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides
DoseLogDan
Member
201
567
Feb 2025
Montana
Mar 7, 2026 at 5:18 PM#24

Relevant to Semaglutide liver fat — here is my latest bloodwork comparison:

Key improvements: A1C 8.4% → 5.5%, triglycerides 205 → 105 mg/dL, hsCRP 8.0 → 1.1 mg/L. All on tirzepatide for 9 months.

The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.

Last edited: Mar 7, 2026 at 6:18 PM
16 21sophie_paris, mel_PDX, Dr.AddMedPHL and 13 others
Reply Quote Save Share Report
Dr.Martinez
Medical Advisor
3,891
28,456
Nov 2023
Boston, MA
Online
Mar 7, 2026 at 5:35 PM#25

Slightly tangential to Semaglutide liver fat but kevin_tulsa reminded me — what is the latest on the oral formulations?

I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.

2 24adam_van, Dr.SurgeonPGH
Reply Quote Save Share Report
1345

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register